Sangamo Therapeutics (SGMOQ) EBIT (2010 - 2025)

Sangamo Therapeutics' EBIT history runs 16 years deep, the most recent figure standing at -$38.2 million for Q4 2025.

• On a quarterly basis, EBIT fell 46.99% year-over-year to -$38.2 million in Q4 2025; TTM through Dec 2025 was -$121.2 million, a 16.61% decrease from a year earlier, with the FY2025 full-year figure at -$121.2 million, down 16.61% from the prior year.
• EBIT retreated to -$38.2 million in Q4 2025 per SGMOQ's latest filing, from -$35.6 million in the prior quarter.
• Across five years, EBIT topped out at $18.0 million in Q1 2023 and bottomed at -$123.6 million in Q2 2023.
• The 5-year median for EBIT is -$45.5 million (2022), against an average of -$44.2 million.
• Across the five-year window, EBIT slumped 1208.73% in 2021 and surged 139.84% in 2023, its largest moves.
• Year by year, EBIT stood at -$39.9 million in 2021, then tumbled by 38.83% to -$55.4 million in 2022, then fell by 12.04% to -$62.1 million in 2023, then soared by 58.12% to -$26.0 million in 2024, then tumbled by 46.99% to -$38.2 million in 2025.
• Per Business Quant, the three latest SGMOQ EBIT figures stand at -$38.2 million (Q4 2025), -$35.6 million (Q3 2025), and -$17.9 million (Q2 2025).